Thymosin Alpha-1 (Zadaxin)

What is thymosin alpha-1?

Thymosin alpha-1 is a small peptide of 28 amino acids, cut from a larger protein called prothymosin alpha, that the body uses as an immune-signaling molecule.

It was first identified in "thymosin fraction 5," a mix of peptides pulled from thymic tissue, by Goldstein and colleagues; the thymus is the organ where T-cells learn to mature, and thymosin alpha-1 is one of the active pieces from that fraction (Goldstein et al., 2009). The peptide sequence is highly conserved across species, which points to a basic biological role. In pharmaceutical form it is sold under the brand name Zadaxin, and its international nonproprietary name is thymalfasin (Goldstein et al., 2009).

How does thymosin alpha-1 work in the body?

It works mainly by moving the immune system's T-cells toward maturity and by tuning the signaling of dendritic cells and Toll-like receptors, so it behaves as an immune modulator rather than a simple "on switch."

Review literature describes several overlapping actions:

• It supports the maturation and differentiation of T-cells, the white blood cells that coordinate adaptive immune responses (King and Tuthill, 2016).
• It enhances dendritic cell function and antigen presentation, the step that helps the immune system recognize targets (King and Tuthill, 2016).
• It modulates Toll-like receptor signaling, including TLR2 and TLR9, on immune cells (King and Tuthill, 2016).
• It has been reported to affect natural killer cell activity and certain cytokine levels in study settings (Goldstein et al., 2009).

Because it tunes existing pathways rather than forcing one fixed response, the literature groups it with "biological response modifiers" (Goldstein et al., 2009).

What has thymosin alpha-1 been studied and approved for?

Marketed as Zadaxin, it carries approved-drug status in a number of national markets, mainly for chronic hepatitis B and as an immune or vaccine adjunct, and it has also been examined in research on sepsis and other conditions, though it is not approved by every regulator and much of the human evidence is modest.

Key research areas described in the reviews include:

• Chronic hepatitis B, where it has been studied on its own and alongside interferon or antiviral therapy, with reported response data described as variable across trials (King and Tuthill, 2016).
• Vaccine and immune support, where it has been studied as an adjunct meant to improve responses in older or immune-compromised groups (Goldstein et al., 2009).
• Sepsis and critical illness, where it has been examined as an immune-modulating adjunct; human data in this setting remains limited and is still under study (King and Tuthill, 2016).

This page is educational. Regulatory status and evidence differ by condition and by jurisdiction, and none of the above is a promise of any outcome.

What dosing has research reported for thymosin alpha-1?

Published clinical work in hepatitis programs most often reported about 1.6 mg given subcutaneously twice weekly, but these are trial-reported figures, not instructions, and any personal dose is a decision for a qualified clinician.

The 1.6 mg twice-weekly figure reflects the marketed hepatitis B regimen described in the review literature (King and Tuthill, 2016). It is reported here only to describe what studies used. It is not a recommendation, a starting point, or a stack. A qualified clinician is the correct source for any personal decision.

What is the half-life of thymosin alpha-1?

Reported plasma half-life is short, on the order of about 2 hours, which is one reason studied schedules use repeated dosing rather than a single injection.

A short half-life means the peptide clears from the blood quickly. Its studied effects come from the signaling it triggers in immune cells, not from staying in circulation, which is why reported schedules space repeated doses over weeks (Goldstein et al., 2009).

What side effects has research reported for thymosin alpha-1?

In studies, thymosin alpha-1 has generally been reported as well tolerated, with mild injection-site reactions the most common issue, but human safety data outside its approved uses is limited and its immune activity means clinical oversight matters.

Reviews describe a low-toxicity profile at the doses studied, with local redness or discomfort at the injection site being the effect most often noted (King and Tuthill, 2016). Two points sit alongside that:

• Because the peptide modulates immune activity, clinicians weigh caution in settings such as autoimmune conditions or organ transplant, where changing immune signaling could matter (Goldstein et al., 2009).
• Long-term and off-label human data is limited, so the full safety picture outside the studied indications is not settled (King and Tuthill, 2016).

None of this is medical advice, and it is not a safety guarantee. A qualified clinician should review individual risk.

How does thymosin alpha-1 compare to LL-37 and thymosin beta-4?

These are three different peptides with three different jobs: thymosin alpha-1 mainly tunes T-cell immunity, LL-37 is a direct antimicrobial host-defense peptide, and thymosin beta-4 (often sold as TB-500) is mainly studied for tissue repair, so they are not interchangeable.

Despite the shared "thymosin" label, thymosin alpha-1 and thymosin beta-4 are structurally and functionally distinct; the shared name reflects their original isolation from the same thymic fraction, not a shared mechanism (Goldstein et al., 2009). For the full evidence on the other two, see the dedicated LL-37 and thymosin beta-4 (TB-500) pages.